Mesa Laboratories, Inc (NASDAQ:MLAB) Prepares For Operational Acceleration Under New CEO

Mesa Laboratories enters an active leadership transition while balance-sheet actions and cash generation support a constructive medium-term outlook. Technical momentum shows near-term weakness, but fundamentals underpin a valuation gap the market may re-price.

Recent News

On March 9, 2026 the company announced CEO Gary Owens will step down on April 12, 2026, and the board appointed Dr. Siddhartha Kadia as President and Chief Executive Officer effective April 13, 2026. The company presented at the J.P. Morgan Healthcare conference on January 14, 2026, outlining its commercial strategy and division-level priorities. The board affirmed the quarterly dividend of $0.16 per share in mid-January 2026.

Technical Analysis

ADX / DI+ / DI-: ADX at 25.45 signals a developing trend strength; DI- increasing while DI+ decreases points to prevailing downside directional pressure that reinforces a cautious near-term price bias.

MACD: MACD sits negative at -0.69 with the MACD trend decreasing and the signal at 1.14, indicating bearish momentum and no bullish MACD crossover to support an immediate momentum reversal.

MRO (Momentum/Regression Oscillator): MRO equals -20.96 and the MRO trend is decreasing; the negative reading implies the current price sits below the WMDST target and signals potential for mean reversion if momentum stabilizes, though the widening MRO gap currently favors continued recovery rather than immediate strength.

RSI: RSI at 52.47 with a decreasing trend reflects neutral-to-weak momentum, consistent with mixed short-term internals rather than an oversold or overbought extreme.

Price vs. Moving Averages and Bands: Last close at $80.60 sits marginally above the 200-day average ($80.38) but below the 20-day average ($90.23) and the 12/26-day EMAs (12-day EMA $86.92 decreasing; 26-day EMA $88.18). The close trades between the lower 2x and 1x Bollinger bands, indicating price near the lower volatility envelope and leaving room for either a stabilizing mean reversion or further downside if momentum picks up.

Volume & Volatility: Intraday volume of 292,256 exceeds 10- and 50-day averages, showing episodic interest; 42- and 52-week volatility both read 4%, and short-term beta (42-day 1.15) implies sensitivity to market moves with moderate idiosyncratic swings.

 


Fundamental Analysis

Profitability & Margins: EBIT equals $7,632,000, producing an EBIT margin of 11.72%, up approximately 10.78% year-over-year and up about 46.43% quarter-over-quarter. The EBIT margin sits below the industry peer mean of 20.83% but shows meaningful sequential improvement that supports margin-led valuation upside.

Revenue & Earnings: Total revenue stands at $65,126,000. Reported EPS equaled $1.76 versus an estimate of $1.47, a beat of $0.29 or roughly 19.7%. Forward EPS equals $1.3475 with a forward P/E of 57.09.

Cash Flow & Liquidity: Operating cash flow totaled $18,754,000 and free cash flow $18,022,000, yielding a free cash flow yield of 4.07%, which exceeds the industry peer mean of 0.91%. Cash and short-term investments equal $28,975,000 while net debt measures $137,152,000, leaving a net leverage profile that management has actively been managing through prior refinancing actions.

Leverage & Coverage: Total debt equals $180,979,000 with debt-to-assets at 41.62% and debt-to-equity near 0.97. Debt-to-EBITDA runs about 13.56x and interest coverage stands at 2.51x, indicating coverage remains limited and debt leverage sits above peer averages; however recent principal reductions and scheduled repayments target leverage reduction.

Efficiency & Returns: Asset turnover sits at 0.1506 and return on equity at 1.94%, both modest; QoQ improvements in return metrics outpace YoY figures, signaling operational gearing that has begun to lift returns during the latest reporting periods.

Valuation: WMDST values the stock as under-valued. Market capitalization equals $442,509,400 with enterprise value $594,513,400 producing an enterprise multiple near 44.54 and an EV-to-revenue ratio of 9.13. Price multiples show a P/E of 45.51 and a price-to-book of 2.37x; relative to the industry peer medians and means provided, several cash-flow and margin metrics imply a valuation gap supportive of re-rating if margins and leverage improvements continue.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-02-03
NEXT REPORT DATE: 2026-05-05
CASH FLOW  Begin Period Cash Flow 20.4 M
 Operating Cash Flow 18.8 M
 Capital Expenditures -732.00 K
 Change In Working Capital 4.5 M
 Dividends Paid -884.00 K
 Cash Flow Delta 8.6 M
 End Period Cash Flow 29.0 M
 
INCOME STATEMENT REVENUE
 Total Revenue 65.1 M
 Forward Revenue 33.4 M
COSTS
 Cost Of Revenue 23.3 M
 Depreciation 1.3 M
 Depreciation and Amortization 5.7 M
 Research and Development 5.0 M
 Total Operating Expenses 57.2 M
PROFITABILITY
 Gross Profit 41.8 M
 EBITDA 13.3 M
 EBIT 7.6 M
 Operating Income 8.0 M
 Interest Income
 Interest Expense 3.0 M
 Net Interest Income -3.04 M
 Income Before Tax 4.6 M
 Tax Provision 966.0 K
 Tax Rate 21.0 %
 Net Income 3.6 M
 Net Income From Continuing Operations 3.6 M
EARNINGS
 EPS Estimate 1.47
 EPS Actual 1.76
 EPS Difference 0.29
 EPS Surprise 19.728 %
 Forward EPS 1.35
 
BALANCE SHEET ASSETS
 Total Assets 434.8 M
 Intangible Assets 278.9 M
 Net Tangible Assets -92.26 M
 Total Current Assets 105.6 M
 Cash and Short-Term Investments 29.0 M
 Cash 29.0 M
 Net Receivables 40.2 M
 Inventory 26.6 M
 Long-Term Investments 17.2 M
LIABILITIES
 Accounts Payable 5.3 M
 Short-Term Debt 5.2 M
 Total Current Liabilities 54.4 M
 Net Debt 137.2 M
 Total Debt 181.0 M
 Total Liabilities 248.2 M
EQUITY
 Total Equity 186.7 M
 Retained Earnings -180.73 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 33.79
 Shares Outstanding 5.525 M
 Revenue Per-Share 11.79
VALUATION
 Market Capitalization 442.5 M
 Enterprise Value 594.5 M
 Enterprise Multiple 44.543
Enterprise Multiple QoQ -17.325 %
Enterprise Multiple YoY -65.041 %
Enterprise Multiple IPRWA high: 158.913
median: 85.622
mean: 83.337
MLAB: 44.543
low: -144.328
 EV/R 9.129
CAPITAL STRUCTURE
 Asset To Equity 2.329
 Asset To Liability 1.752
 Debt To Capital 0.492
 Debt To Assets 0.416
Debt To Assets QoQ -5.946 %
Debt To Assets YoY 80.294 %
Debt To Assets IPRWA high: 0.717
MLAB: 0.416
mean: 0.279
median: 0.262
low: 0.009
 Debt To Equity 0.969
Debt To Equity QoQ -9.15 %
Debt To Equity YoY 49.104 %
Debt To Equity IPRWA high: 2.909
MLAB: 0.969
mean: 0.536
median: 0.472
low: 0.01
PRICE-BASED VALUATION
 Price To Book (P/B) 2.37
Price To Book QoQ 3.932 %
Price To Book YoY -48.189 %
Price To Book IPRWA high: 10.911
mean: 5.97
median: 5.854
MLAB: 2.37
low: 0.42
 Price To Earnings (P/E) 45.508
Price To Earnings QoQ 29.79 %
Price To Earnings YoY -109.054 %
Price To Earnings IPRWA high: 269.298
mean: 119.908
median: 86.718
MLAB: 45.508
low: -315.07
 PE/G Ratio 0.156
 Price To Sales (P/S) 6.795
Price To Sales QoQ 1.394 %
Price To Sales YoY -39.869 %
Price To Sales IPRWA high: 30.65
median: 23.476
mean: 20.13
MLAB: 6.795
low: 0.541
FORWARD MULTIPLES
Forward P/E 57.092
Forward PE/G 0.196
Forward P/S 13.252
EFFICIENCY OPERATIONAL
 Operating Leverage 7.889
ASSET & SALES
 Asset Turnover Ratio 0.151
Asset Turnover Ratio QoQ 7.344 %
Asset Turnover Ratio YoY 6.758 %
Asset Turnover Ratio IPRWA high: 0.371
MLAB: 0.151
median: 0.133
mean: 0.127
low: 0.003
 Receivables Turnover 1.622
Receivables Turnover Ratio QoQ 5.671 %
Receivables Turnover Ratio YoY 1.774 %
Receivables Turnover Ratio IPRWA high: 2.907
mean: 1.882
median: 1.867
MLAB: 1.622
low: 0.47
 Inventory Turnover 0.859
Inventory Turnover Ratio QoQ 2.52 %
Inventory Turnover Ratio YoY 7.69 %
Inventory Turnover Ratio IPRWA high: 1.821
MLAB: 0.859
mean: 0.671
median: 0.548
low: 0.167
 Days Sales Outstanding (DSO) 56.273
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 141.954
Cash Conversion Cycle Days QoQ -4.892 %
Cash Conversion Cycle Days YoY -8.238 %
Cash Conversion Cycle Days IPRWA high: 453.393
mean: 171.614
median: 165.533
MLAB: 141.954
low: -118.454
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 1.271
 CapEx To Revenue -0.011
 CapEx To Depreciation -0.576
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 347.7 M
 Net Invested Capital 352.8 M
 Invested Capital 352.8 M
 Net Tangible Assets -92.26 M
 Net Working Capital 51.2 M
LIQUIDITY
 Cash Ratio 0.533
 Current Ratio 1.942
Current Ratio QoQ -3.743 %
Current Ratio YoY 173.09 %
Current Ratio IPRWA high: 12.891
mean: 2.701
MLAB: 1.942
median: 1.893
low: 0.168
 Quick Ratio 1.454
Quick Ratio QoQ 0.734 %
Quick Ratio YoY 173.923 %
Quick Ratio IPRWA high: 12.347
mean: 2.054
median: 1.508
MLAB: 1.454
low: 0.437
COVERAGE & LEVERAGE
 Debt To EBITDA 13.56
 Cost Of Debt 1.291 %
 Interest Coverage Ratio 2.514
Interest Coverage Ratio QoQ 48.006 %
Interest Coverage Ratio YoY 1043.066 %
Interest Coverage Ratio IPRWA high: 33.446
median: 25.964
mean: 20.981
MLAB: 2.514
low: -66.822
 Operating Cash Flow Ratio 0.194
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 20.161
DIVIDENDS
 Dividend Coverage Ratio 4.106
 Dividend Payout Ratio 0.244
 Dividend Rate 0.16
 Dividend Yield 0.002
PERFORMANCE GROWTH
 Asset Growth Rate 1.045 %
 Revenue Growth 7.226 %
Revenue Growth QoQ 260.399 %
Revenue Growth YoY -16.54 %
Revenue Growth IPRWA high: 20.682 %
median: 12.969 %
mean: 10.148 %
MLAB: 7.226 %
low: -11.548 %
 Earnings Growth 291.111 %
Earnings Growth QoQ 2279.524 %
Earnings Growth YoY -319.706 %
Earnings Growth IPRWA MLAB: 291.111 %
high: 188.889 %
mean: 10.336 %
median: 6.383 %
low: -142.105 %
MARGINS
 Gross Margin 64.176 %
Gross Margin QoQ 4.414 %
Gross Margin YoY 1.445 %
Gross Margin IPRWA high: 89.02 %
median: 64.538 %
MLAB: 64.176 %
mean: 62.803 %
low: 1.515 %
 EBIT Margin 11.719 %
EBIT Margin QoQ 46.433 %
EBIT Margin YoY 1077.789 %
EBIT Margin IPRWA high: 33.51 %
median: 20.883 %
mean: 20.828 %
MLAB: 11.719 %
low: -143.917 %
 Return On Sales (ROS) 12.245 %
Return On Sales QoQ 57.431 %
Return On Sales YoY 1130.653 %
Return On Sales IPRWA high: 35.479 %
mean: 22.141 %
median: 21.965 %
MLAB: 12.245 %
low: -146.78 %
CASH FLOW
 Free Cash Flow (FCF) 18.0 M
 Free Cash Flow Yield 4.073 %
Free Cash Flow Yield QoQ 132.477 %
Free Cash Flow Yield YoY 64.102 %
Free Cash Flow Yield IPRWA MLAB: 4.073 %
high: 3.107 %
median: 0.969 %
mean: 0.91 %
low: -10.193 %
 Free Cash Growth 152.763 %
Free Cash Growth QoQ -78.379 %
Free Cash Growth YoY -62.379 %
Free Cash Growth IPRWA MLAB: 152.763 %
high: 115.002 %
mean: 4.771 %
median: -0.761 %
low: -446.345 %
 Free Cash To Net Income 4.965
 Cash Flow Margin 16.195 %
 Cash Flow To Earnings 2.906
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 0.839 %
Return On Assets QoQ 46.678 %
Return On Assets YoY -323.138 %
Return On Assets IPRWA high: 5.088 %
mean: 1.999 %
median: 1.556 %
MLAB: 0.839 %
low: -17.15 %
 Return On Capital Employed (ROCE) 2.006 %
 Return On Equity (ROE) 0.019
Return On Equity QoQ 40.159 %
Return On Equity YoY -280.0 %
Return On Equity IPRWA high: 0.174
mean: 0.031
median: 0.028
MLAB: 0.019
low: -0.303
 DuPont ROE 1.988 %
 Return On Invested Capital (ROIC) 1.708 %
Return On Invested Capital QoQ 57.13 %
Return On Invested Capital YoY 153.037 %
Return On Invested Capital IPRWA high: 5.899 %
mean: 2.696 %
median: 2.127 %
MLAB: 1.708 %
low: -14.233 %

Six-Week Outlook

Near-term price bias remains mixed-to-cautious. Technical internals show bearish momentum (declining MACD, rising DI-) while the MRO suggests the market currently trades below WMDST’s target, implying scope for a corrective rebound if momentum stabilizes. Price currently sits below short-term averages but above the 200-day average, favoring a consolidation range between the lower Bollinger band and the 20-day average until a clear momentum shift appears. Watch for a resolution of the leadership transition and follow-on corporate communications that may influence operational guidance and leverage trajectories; those events will likely matter more to price action than current short-term momentum readings.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. (NASDAQ:MLAB) develops and manufactures a diverse range of life sciences tools and quality control products. Serving markets across North America, Europe, the Asia Pacific, and globally, Mesa Laboratories addresses critical needs in various industries. The Sterilization and Disinfection Control segment provides biological, chemical, and cleaning indicators, essential for evaluating sterilization and decontamination processes in the pharmaceutical, medical device, and healthcare sectors. This segment also extends testing and laboratory services to dental and pharmaceutical industries. In the Clinical Genomics segment, Mesa Laboratories offers the MassARRAY system, a genetic analysis tool, along with consumables like chips, panels, and chemical reagents. These tools support clinical labs in DNA sample analysis for genetic disease testing, pharmacogenetics, oncology, and more. The Biopharmaceutical Development segment delivers automated systems for protein analysis and peptide synthesis, including Gyrolab and PurePep product lines. The Calibration Solutions segment provides quality control products for measuring critical parameters in environmental and process monitoring, as well as medical device and pharmaceutical manufacturing. Products include continuous monitoring systems, dialysate meters, data loggers, and gas flow calibration equipment, marketed under brands such as DialyGuard, ViewPoint, and DataTrace. Established in 1982, Mesa Laboratories is headquartered in Lakewood, Colorado.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.